06 | 11 | 19Nanoform wins the CPhI Excellence in Pharma Award for Formulation Nanoform, an innovative medicine enabling nanotechnology company, has won the Excellence in Pharma Award for Formulation at the prestigious CPhI Pharma Awards.
10 | 10 | 19Nanoform nominated for CPhI Award! We are delighted to have been shortlisted as a finalist for the CPhI Award in the Excellence in Pharma: Formulation category.
25 | 09 | 19Nanoform and AstraZeneca Initiate Technology Evaluation Nanoform is delighted to announce the initiation of a technology evaluation of Nanoform’s Proprietary CESS Technology across a range of AstraZeneca’s proprietary pharmaceutical products.
10 | 09 | 19Nanoform strengthens board with appointment of Mads Laustsen Nanoform has appointed Mads Laustsen as a non-executive board member. This appointment will further strengthen the experienced Nanoform board and support the company as it increases its ability to deliver nanonized APIs for global partners across the pipeline from late stage drug discovery to commercial.
03 | 09 | 19Nanoform appoints Mike Rea as Strategic Innovation Advisor Nanoform has appointed Mike Rea as its Strategic Innovation Advisor. The role will involve working closely with Nanoform to maximise the value its proprietary nanonization technology can deliver to pharmaceutical partners and patients globally.
10 | 07 | 19Nanoform appoints Director of Investor Relations following international growth Nanoform has appointed Henri von Haartman as Director of Investor Relations. The newly created role will enrich investor relations as Nanoform seeks to further its shareholder base and continue its international growth, including expansion into the US market.
03 | 07 | 19Nanoform continues strategic growth with €10 million private placement Nanoform announced the completion of a private placement totaling €10 million, with Ilmarinen Mutual Pension Insurance Company and Mandatum Life Insurance Company (Sampo Group) acting as anchor investors.
27 | 06 | 19Nanoform announces major rebrand Nanoform has unveiled a new brand identity and website. The evolution of Nanoform’s brand reflects how the company is using innovation to transform the pharmaceutical industry and support its global partners as they develop life-changing medicines.
30 | 05 | 19Our CCO, Christian Jones, interviewed at EBD Group’s BIO-Europe Spring 2019. Our CCO, Christian Jones, recently discussed the advantages of our nanonization services with Mike Ward at EBD Group’s BIO-Europe Spring 2019. Watch the Scrip video to learn more:
28 | 05 | 19Nanoform accelerates growth with Director of Project Management appointment Nanoform accelerates growth with Director of Project Management appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, will appoint Miguel Cansado as its Director of Project Management.
28 | 05 | 19Nanoform awarded with a Seal of Excellence from the European Commission Nanoform awarded with a Seal of Excellence from the European Commission Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has received a Seal of Excellence from the European Commission for its “Nanomedicines of Tomorrow” project.
29 | 04 | 19Nanoform strengthens GMP capabilities with Head of Manufacturing appointment Nanoform strengthens GMP capabilities with Head of Manufacturing appointment Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, has appointed Dr David Rowe as its Head of Manufacturing.